Live Investor briefing, page-9

Shellbell, please don't think that I have a handle on “all the complex sciency stuff”. A very rough and shallow grasp is probably more accurate!

This UNIVERSAL RECEPTOR IMMUNE CELL THERAPY patent seems to me to broadly cover all the various aspects of the OmniCAR platform, most of which we are now familiar with.

So the patent description and claims cover things like:

• how a method of dosing periodically and ceasing the dosing of tagged binders is used in order to enhance recombinant immune cell persistence.
• the timing and amount of dosing.
• the use of either one or more binders.
• specifically, the use of binders targeting the HER2 receptor, EGFRvIII receptor, CD33 receptor, CLL1 receptor and the IL-13Ra2 receptor (so covering the 4 antigens being targeted in PTX’s 3 cancer programs + one more).
• its use alone or in conjunction with another form of treatment (such as chemotherapy).
• the use of immune cells comprising T cells, NK cells, dendritic cells, myeloid cells, macrophages, stem cells or a combination thereof.
• the use of T cells comprising cytotoxic T cells, gamma delta T cells, T regulatory cells or iNKT cells.
• its use in the treatment of cancer, infection or inflammatory disease.
• its use in a broad range of cancers, both solid and blood.
• its use of a vector.

and in a reference to Cellpryme-M

• its use with enriched T effector memory cells and T central memory cells.
• its use with a specific ratio of CD8+ immune cells.

So yes, Shellbell, the patent does reflect the pre-clinical optimisation of OmniCar.

The claims, by the way, are restricted to use of autologous cells. Also, I note that while most of the patent claims seem to have been initially accepted as novel, acceptance of inventive step may pose more of a challenge.